: iStockAnalyst.com Symbols Feed

This Fall Will Be Crazy For These Biotech Stocks

Fri, 16 Oct 2009 18:50:27 GMT

Most speculators have it all wrong when it comes to biotech trading... They'll buy biotech stocks ahead of FDA decisions, hoping an approval will bring 100% overnight gains. But more often than not, the market is one step ahead. The stock price will creep up as everyone anticipates good news.[More...]

BioMedReports FDA Calendar: Seven Laggard Trades

Wed, 17 Jun 2009 20:29:05 GMT

Below are seven companies from the BioMedReports.com FDA Calendar database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yah (...)[More...]

FDA, Clinical Trial Updates: GTXI, GSK, XNPT, RMTI

Tue, 28 Apr 2009 16:12:00 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA (...)[More...]

Earnings Preview for Feb 9-13 - Earnings Preview

Fri, 06 Feb 2009 18:52:00 GMT

Activision Blizzard Inc. (ATVI) could top expectations. IntercontinentalExchange, Inc. (ICE) and Terex Corporation (TEX) could miss. Though nearly 400 companies are scheduled to report, traders are going to keep a close eye on Washington. Treasury Secretary Timothy Geithner will announce a revised bank bailout plan on Monday. This plan could include the creation of a bad bank to absorb distressed debts (what TARP was[More...]

Earnings Preview For Nov 3 - 7 - Earnings Preview

Sat, 01 Nov 2008 01:58:00 GMT

Companies that could issue positive surprises include Becton, Dickinson and Company (BDX), SucessFactors (SFSF) and Sunoco (SUN). Penn Virginia Corporation (PVA) could potentially disappoint investors. The Week's Events November has historically been one of the best months for the major markets, according to the[More...]

Analyst Comments: XenoPort, Standard Motor, Vital Images, Ingram Micro, Bank of Ireland, Napster

Fri, 19 Sep 2008 13:55:00 GMT

XenoPort, Inc.?s (XNPT) lead candidate is Solzira (XP-13512), a Transported Prodrug of gabapentin. XenoPort is partnered with GlaxoSmithKline (GSK) for development and commercialization in the U.S. and select countries outside the U.S. The drug has comple[More...]

Analyst Comments: BorgWarner, CarMax, Primedia, Sempra, XenoPort

Mon, 23 Jun 2008 16:47:30 GMT

BorgWarner Inc. (BWA) is expected to benefit from the growing demand for its strong technology-based product portfolio. About $1.95 billion of new powertrain business is expected between 2008 and 2010. The company has healthy financials with low debt and has taken further initiatives to maintain margins in the challenging North American industry environment. However, due to high...[More...]

Periodicals Wrap-Up for Wednesday, June 4th

Wed, 04 Jun 2008 14:37:59 GMT

In a move to help cut expenses and save on fuel prices, UAL Corp. (UAUA), parent of United Airlines, will reduce its 460 airplane fleet by 70 jets. Not yet known is how may jobs will be affected, the Wall Street Journal reported…[More...]

Analyst Comments: Schering-Plough, Iron Mountain, I-Flow, Regency Centers, XenoPort, EOG Resources, SABESP

Thu, 03 Apr 2008 17:38:20 GMT

Schering-Plough (SGP) is engaged in the development, manufacturing and marketing of pharmaceutical products around the world. The company focuses on prescription drugs, animal health, foot-care and sun-care products. In November 2007, Schering-Plough closed acquired Organon Bio for a mix of $15 billion in cash/debt/equity. Our previous expectations of strong earnings growth as a result of outperformance of key drugs such as Remicade and Vytorin/Zetia have been substantially muted. Recent negative comments...[More...]

Analyst Comments: Genta, XenoPort, Theravance, Palm,

Wed, 20 Feb 2008 08:02:12 GMT

Genta, Incorporated (GNTA) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer. The company's leading candidate, Genasense, for the treatment of CLL [chronic lymphocytic leukemia], got a non-approvabl[More...]

XenoPort to sell 2.5 million shares

Tue, 07 Jul 2009 20:49:00 GMT

SANTA CLARA, Calif. - Biopharmaceutical company XenoPort Inc. on Tuesday said it will sell 2.5 million shares of its common stock, increasing the number of outstanding shares by more than 9 percent.
The proceeds will go to fund research and development of its drug candidates, possible sales and marketing activities and for general corporate purposes, the company said in a regulatory filing.
XenoPort also intends to grant the underwriters a 30-day option to purchase up to 375,000 additional shares to cover over-allotments, if any.

[More...]

XenoPort Reports Second Quarter Financial Results

Wed, 05 Aug 2009 20:16:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today financial results for the second quarter and six months ended June 30, 2009. Revenues for the second quarter were $1.8 million, compared to $11.5 million for the same period in 2008. Net loss for the second quarter was $20.9 million, compared to a net loss of $12.4 million for the same period in 2008. At June 30, 2009, XenoPort had cash, cash equivalents and short-term investments of $123.5 million.[More...]

XenoPort Announces Astellas’ Plans to File an NDA for XP13512 in Japan

Mon, 03 Aug 2009 10:27:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today that Astellas Pharma Inc. plans to file a new drug application (NDA) in Japan for XP13512 (known as ASP8825 by Astellas) as a potential treatment for moderate-to-severe primary restless legs syndrome (RLS) in the second half of its 2009 fiscal year, which ends on March 31, 2010. The evidence of efficacy for the NDA filing will be based on data from Astellas’ successful Phase 2 study in RLS patients conducted in Japan and XenoPort’s clinical program conducted in the United States. Based on the outcome of a Pharmaceutical and Medical Devices Agency (PMDA) consultation meeting, Astellas has concluded that Phase 3 clinical studies in Japan will not be required for the NDA filing.[More...]

XenoPort to Release Second Quarter Financial Results on August 5, 2009

Thu, 23 Jul 2009 17:26:00 GMT

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second quarter financial results on August 5, 2009 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.[More...]

XenoPort Announces Pricing of Public Offering of Common Stock

Wed, 08 Jul 2009 13:55:00 GMT

XenoPort, Inc. (Nasdaq: XNPT) announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $19.00 per share.
XenoPort has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments, if any.
All of the shares are being offered by XenoPort.

[More...]

XenoPort Announces Proposed Public Offering of Common Stock

Tue, 07 Jul 2009 20:51:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today that it is offering to sell, subject to market and other conditions, 2,500,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.
Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. are acting as joint book-runners for the offering.
Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, New York 10014 (Email prospectus@morganstanley.com) or Goldman, Sachs & Co., Attn: Registration Department, 85 Broad Street, 20th Floor, New York, New York, 10004 (Telephone number 1-866-471-2526 or prospectus-ny@ny.email.gs.com).

[More...]

XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity

Tue, 30 Jun 2009 10:26:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study. AP was well tolerated during the trial.[More...]

XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference

Fri, 12 Jun 2009 14:26:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Piper Jaffray Fourth Annual Europe Conference. The live presentation will occur at 5:00 a.m. Pacific Daylight Time (12:00 p.m. GMT) on Tuesday, June 23, 2009. A replay of the presentation will also be available.[More...]

XenoPort to Present at the Goldman Sachs 30th Annual Global Healthcare Conference

Wed, 03 Jun 2009 21:49:00 GMT

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Goldman Sachs 30th Annual Global Healthcare Conference. The live presentation will occur at 8:20 a.m. Pacific Time (11:20 a.m. Eastern Time) on Tuesday, June 9, 2009. A replay of the presentation will also be available.[More...]

XenoPort Data Presented at Digestive Disease Week Meeting Demonstrates Arbaclofen Placarbil Monotherapy Reduces Heartburn and Regurgitation in GERD Patients Previously Treated with PPIs

Mon, 01 Jun 2009 20:57:00 GMT

XenoPort, Inc. (Nasdaq: XNPT) announced today that additional data from a Phase 2 clinical trial demonstrated that arbaclofen placarbil (AP), also known as XP19986, significantly reduced symptoms in gastroesophageal reflux disease (GERD) patients who previously experienced at least a partial response to proton pump inhibitor (PPI) therapy. The data were presented today by Nimish B. Vakil, M.D., FACG, of the University of Wisconsin Medical School at the Digestive Disease Week 2009 annual meeting in Chicago, IL.[More...]

XenoPort to Present at the Deutsche Bank 34th Annual Health Care Conference

Wed, 13 May 2009 17:56:00 GMT

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 34th Annual Deutsche Bank Health Care Conference. The live presentation will occur at 12:15 p.m. Pacific Time (3:15 p.m. Eastern Time) on Tuesday, May 19, 2009. A replay of the presentation will also be available.[More...]